Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Darier's disease Initial: 10 mg/day for 2-4 wk, then adjust to 25-50 mg/day according to response. Congenital ichthyosis; Severe psoriasis; Severe lichen planus Initial: 25 or 30 mg/day for 2-4 wk, then adjust according to response. Usual range: 25-50 mg/day for 6-8 wk. Max: 75 mg/day.
Dosage Details
Darier's disease
Adult: Initially, 10 mg daily for 2-4 wk, adjusted thereafter to 25-50mg daily according to response.

Congenital ichthyosis, Severe lichen planus, Severe psoriasis
Adult: Initially, 25 or 30 mg daily for 2-4 wk, adjusted thereafter according to response. Usual range: 25-50 mg daily for 6-8 wk. Max: 75 mg daily.
Renal Impairment
Severe: Contraindicated.
Hepatic Impairment
Severe: Contraindicated.
Should be taken with food. Take w/ main meals or w/ a glass of milk.
Hyperlipidaemia. Severe hepatic and renal impairment. Pregnancy and lactation. Concomitant use w/ methotrexate, tetracyclines, vit A or other retinoids, low dose progesterone-only products (minipills).
Special Precautions
Females of reproductive potential.
Adverse Reactions
Cheilitis, alopecia, skin peeling, rhinitis, dry skin, nail disorder, pruritus, rigors, xerophthalmia, dry mouth, epistaxis, arthralgia, spinal hyperostosis, rash, hyperaesthesia, paraesthesia, paronychia, skin atrophy, decreased night vision, abdominal pain; abnormal hair texture; dermatitis; diarrhoea; epidermal fragility; erythema; headache; myalgia; nausea, vomiting; peripheral oedema; psudomotor cerebri, depression and other psychiatric symptoms (e.g. aggressive feelings, suicidal thoughts); increased liver enzymes, uric acid, BUN, triglycerides and cholesterol levels; increased or decreased electrolytes, haematocrit, Hb, glucose.
Potentially Fatal: Hepatotoxicity, fulminant pancreatitis.
Patient Counseling Information
Avoid exposure to natural or artificial sunlight. This drug may decrease night vision, if affected, do not drive or operate any vehicle.
Monitor plasma lipid, glucose levels (esp in diabetic patients) regularly; bone abnormalities (long-term use). Perform LFTs; pregnancy tests (2 negative tests prior to therapy, mthly during treatment and 3 mthly for 3 yr after stopping therapy).
Drug Interactions
May reduce the protein binding of phenytoin.
Potentially Fatal: Increased risk of hepatitis w/ methotrexate. Increased intracranial pressure w/ tetracyclines. Risk of hypervitaminosis A w/ concomitant vit A and/or other oral retinoids. Interferes w/ the contraceptive effect of low dose progesterone-only products (minipills).
Food Interaction
Increased absorption w/ food. Increased duration of teratogenic effects w/ concurrent ingestion of alcohol.
Description: Acitretin is a synthetic aromatic analogue of retinoic acid and an active metabolite of etretinate. The exact mechanism of action has not been established but may be mediated by activation of α, β and γ subtypes of retinoic acid and retinoid X receptors to inhibit the expression of the pro-inflammatory cytokines interleukin-6 (IL-6), migration inhibitory factor-related protein-8 (MRP-8), and interferon-γ, resulting to normalisation of epidermal cell proliferation, differentiation and keratinisation.
Onset: Full effect: 2-3 mth. Improvement: W/in 8 wk.
Absorption: Absorbed in the GI tract. Increased absorption w/ food. Bioavailability: Approx 60-70%. Time to peak plasma concentration: 1-5 hr.
Distribution: Distributed into skin w/ highest concentration in stratum corneum; semen (small amounts). Penetrates adipose tissue, crosses the placenta and enters breast milk. Plasma protein binding: >99.9%, mainly to albumin.
Metabolism: Undergoes extensive hepatic metabolism and interconversion via simple isomerization to 13-cis-acitretin.
Excretion: Via Urine (16-53%) and faeces (34-54%). Elimination half-life: Approx 2 days.
Chemical Structure

Click on icon to see table/diagram/image
Store between 20-25°C.
ATC Classification
D05BB02 - acitretin ; Belongs to the class of systemic retinoids used in the treatment of psoriasis.
Disclaimer: This information is independently developed by MIMS based on Acitretin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by
  • Neotigason
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in